Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I trial of NaV 1.8 inhibitor for acute and chronic pain conditions

Trial Profile

A Phase I trial of NaV 1.8 inhibitor for acute and chronic pain conditions

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NaV-1.8-inhibitor-Grunenthal (Primary)
  • Indications Pain
  • Focus Adverse reactions

Most Recent Events

  • 02 Mar 2026 New trial record
  • 18 Feb 2026 According to Grunenthal media release, first healthy volunteers have been enrolled in this study. Full results of the trial are expected in the second half of 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top